SCHEMBL5777210

SCHEMBL5777210

CCOC(=O)c1c(Nc2ccccc2)n(-c2ccccc2)c2cnccc2c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.47
RECQL P46063 1/20 0.46
SPR P35270 1/20 0.45
NPEPPS P55786 4/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM5A P29375 1/20 0.41
KDM5B Q9UGL1 1/20 0.41
PDE4B Q07343 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
BRAF P15056 1/20 0.41
ATM Q13315 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
PDE4D Q08499 1/20 0.40
TP53 P04637 1/20 0.40
THRB P10828 1/20 0.40
KDM4E B2RXH2 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5871674 0.79 SMN1; SMN2 (0.50) CSF1RRECQLSPRMEN1KMT2A
SCHEMBL5872120 0.73 LMNA (0.48) CSF1RMEN1KMT2AALDH1A1GAA
SCHEMBL22172011 0.69 KDM4C (0.47) ALDH1A1ATMKDM4EHTT
SCHEMBL22845404 0.69 ALDH1A1 (0.47) RECQLMEN1KMT2AALDH1A1GAA
SCHEMBL25942232 0.68 ALDH1A1 (0.51) SPRKMT2AKDM5AKDM5BALDH1A1
SCHEMBL18044696 0.68 ALDH1A1 (0.50) CSF1RRECQLMEN1KMT2AALDH1A1
SCHEMBL11789226 0.68 MAPT (0.60) RECQLMEN1KMT2AALDH1A1GAA
SCHEMBL5777622 0.67 CDK4 (0.41) ALDH1A1GAA
SCHEMBL22172017 0.66 KDM4E (0.53) KMT2AATMKDM4EHTT
SCHEMBL8287988 0.66 CSF1R (0.47) CSF1RSPRPDE4BALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513840-B1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF DIABETES AND DIABETES-RELATED DISORDERS BAYER PHARMACEUTICALS CORP (US) 2006-10-04 EP disclosed
US-20060009483-A1 Compounds and compositions for the treatment of diabetes and diabetes-related disorders BAYER PHARMACEUTICALS CORPORATION (US) 2006-01-12 US disclosed
EP-1513840-A2 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF DIABETES AND DIABETES-RELATED DISORDERS Bayer Pharmaceuticals Corporation (US) 2005-03-16 EP disclosed
WO-2003101988-A2 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF DIABETES AND DIABETES-RELATED DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2003-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009483-A1 Compounds and compositions for the treatment of diabetes and diabetes-related disorders IAPP, GPR119, PNLIP CSF1R 4716/4885RECQL 792/4885SPR 2490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.